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Identiﬁcation of a Novel Invasion-Promoting Region in Insulin
Receptor Substrate 2
Jose Mercado-Matos,a Jenny Janusis,a Sha Zhu,a Samuel S. Chen,a Leslie M. Shawa
aDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester,
Massachusetts, USA
ABSTRACT Although the insulin receptor substrate (IRS) proteins IRS1 and IRS2
share considerable homology and activate common signaling pathways, their contri-
butions to breast cancer are distinct. IRS1 has been implicated in the proliferation
and survival of breast tumor cells. In contrast, IRS2 facilitates glycolysis, invasion, and
metastasis. To determine the mechanistic basis for IRS2-dependent functions, we in-
vestigated unique structural features of IRS2 that are required for invasion. Our stud-
ies revealed that the ability of IRS2 to promote invasion is dependent upon up-
stream insulin-like growth factor 1 receptor (IGF-1R)/insulin receptor (IR) activation
and the recruitment and activation of phosphatidylinositol 3-kinase (PI3K), functions
shared with IRS1. In addition, a 174-amino-acid region in the IRS2 C-terminal tail,
which is not conserved in IRS1, is also required for IRS2-mediated invasion. Impor-
tantly, this “invasion (INV) region” is sufﬁcient to confer invasion-promoting ability
when swapped into IRS1. However, the INV region is not required for the IRS2-
dependent regulation of glucose uptake. Bone morphogenetic protein 2-inducible
kinase (BMP2K) binds to the INV region and contributes to IRS2-dependent invasion.
Taken together, our data advance the mechanistic understanding of how IRS2 regu-
lates invasion and reveal that IRS2 functions important for cancer can be indepen-
dently targeted without interfering with the metabolic activities of this adaptor pro-
tein.
KEYWORDS breast cancer, IGF-1R, IRS2, invasion, PI3K
Insulin receptor substrate 2 (IRS2) is a cytoplasmic adaptor protein that promotesbreast cancer progression (1). Although IRS2 shares signiﬁcant homology and the
ability to activate common signaling pathways with its homologous family member
IRS1, these adaptor proteins play distinct functional roles in breast cancer (2). The IRS1
gene is an estrogen receptor (ER)-regulated gene, and it is expressed at high levels in
the ER, luminal subtype of breast cancer (3–6). IRS1 interacts with the ER to positively
regulate its transcriptional activity at estrogen response genes (6, 7). In this regard,
tamoxifen response in breast cancer patients correlates with nuclear IRS1 expression
(8). In vitro studies imply a role for IRS1 in the regulation of proliferation and survival in
luminal breast carcinoma cells (9, 10). IRS1 expression decreases as ER expression or
function is lost in more poorly differentiated, invasive breast tumors (11). In contrast,
IRS2 is expressed at higher levels in ER breast carcinoma cells of the basal-like/triple-
negative breast cancer (TNBC) subtypes, and it regulates tumor cell migration, invasion,
and glycolytic metabolism (1, 12–14). The different functions of IRS1 and IRS2 in breast
cancer are further evidenced by the fact that mouse mammary tumors that lack IRS2
have signiﬁcantly diminished ability to metastasize to the lungs, whereas tumors
lacking IRS1 but expressing elevated IRS2 have enhanced metastatic potential (1, 15).
IRS2 expression at the cell membrane in human breast tumors correlates with de-
Received 8 November 2017 Returned for
modiﬁcation 27 December 2017 Accepted
15 April 2018
Accepted manuscript posted online 23
April 2018
CitationMercado-Matos J, Janusis J, Zhu S,
Chen SS, Shaw LM. 2018. Identiﬁcation of a
novel invasion-promoting region in insulin
receptor substrate 2. Mol Cell Biol 38:e00590-
17. https://doi.org/10.1128/MCB.00590-17.
Copyright © 2018 American Society for
Microbiology. All Rights Reserved.
Address correspondence to Leslie M. Shaw,
leslie.shaw@umassmed.edu.
RESEARCH ARTICLE
crossm
July 2018 Volume 38 Issue 14 e00590-17 mcb.asm.org 1Molecular and Cellular Biology
 o
n
 July 12, 2018 by UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
creased overall survival, a ﬁnding that further supports a role for IRS2 in more aggres-
sive tumor behavior (16).
The IRS proteins are recruited to cell surface receptors, where they are phosphory-
lated on tyrosine residues within their C-terminal tails, either directly by receptor
tyrosine kinases or by associated nonreceptor kinases (i.e., the JAK family) (17, 18).
These phosphorylation events generate SH2-binding sites for the recruitment and
activation of signaling effectors that modify cell behavior. Common SH2-dependent
binding partners that are recruited to IRS1 and IRS2 include phosphatidylinositol
3-kinase (PI3K), growth factor receptor-bound protein 2 (GRB-2), SHP2, and Src family
kinases (SFKs) (19–23). The IRS proteins were ﬁrst characterized as regulators of
signaling downstream of the insulin receptor (IR) and the insulin-like growth factor 1
receptor (IGF-1R), but they can also serve as signaling intermediates of additional
growth factor, cytokine, and integrin receptors (18, 24–28). Many of these receptors
have been implicated in tumor development, growth, and metastasis, highlighting the
importance of understanding the mechanism(s) by which the IRS proteins mediate their
distinct downstream signaling outcomes.
The fact that IRS1 and IRS2 signal downstream of similar upstream receptors and
activate common signaling pathways while the cellular responses to their signaling are
unique implies that IRS function involves unique structural features of IRS1 and IRS2
that confer their distinct mechanisms of action. The IRS proteins have well-conserved,
stable N-terminal PH and PTB domains that mediate their interactions with upstream
receptors, followed by long, disordered tails that share less homology (29). They are
considered to be intrinsically disordered proteins (IDPs) because of their overall ab-
sence of secondary or tertiary structure beyond the PH and PTB domains. This lack of
stable structure is thought to allow dynamic intramolecular interactions to occur that
rapidly integrate upstream signals to alter downstream function through the recruit-
ment of signaling effectors (30). To date, interacting partners that bind uniquely to IRS1
or IRS2 that would explain their functional differences in cancer have not been
reported. In the current study, we investigated the mechanism by which IRS2 selectively
regulates one function, invasion. Our structure-function dissection of IRS2 identiﬁed a
novel functional region within the C-terminal tail that is not conserved in IRS1, which
we have termed the invasion (INV) region. This region is required for the ability of IRS2
to promote invasion but not glucose uptake by a mechanism that may involve the
recruitment of novel effector molecules.
RESULTS
The IGF-1R/PI3K axis is involved in IRS2-mediated invasion. In previous studies,
we demonstrated that mouse mammary tumor cells and human breast carcinoma cells
lacking IRS2 expression are deﬁcient in their ability to invade (1, 31). In contrast, loss of
IRS1 expression enhances invasion (1). To further our understanding of how IRS2
selectively regulates tumor cell invasion, double-Irs1/Irs2-null polyomavirus middle T
mouse mammary tumor (PyMT:Irs1/2/) cells were used to assess Irs2 function in the
absence of Irs1 expression. Restoration of IRS2 but not IRS1 expression in these
double-Irs-null cells signiﬁcantly increased invasion (Fig. 1A and 2C). IRS2 function is
regulated by tyrosine phosphorylation in response to upstream receptor activation. To
determine if IGF-1R or IR regulates IRS2-dependent invasion, assays were performed in
the presence of the dual IGF-1R/IR small-molecule inhibitor BMS754807 (32). Cells were
pretreated for 4 h and then incubated with inhibitor throughout the Matrigel Transwell
invasion assay (Corning). Inhibition of IR/IGF-1R did not alter the invasion of PyMT:Irs1/
2/ cells expressing empty vector (EV). In contrast, IRS2-dependent tumor cell inva-
sion was inhibited in a dose-dependent manner (Fig. 1A). Cells treated in parallel with
BMS754807 were assayed for IGF-1R/IR phosphorylation and activation of AKT, as a
measure of PI3K activity, to conﬁrm inhibition of the pathway. Receptor inhibition was
sustained throughout the time period of the assay at a concentration of 1 M
BMS754807 (Fig. 1B).
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Both IRS1 and IRS2 can recruit and activate PI3K, but only IRS2 promotes invasion (1).
For this reason, we examined if the ability of IRS2 to regulate PI3K signaling is required
for IRS2-mediated invasion. Previous work by our group identiﬁed four essential
tyrosines in murine Irs2 (Y649, Y671, Y734, and Y814) that are conserved in human IRS2
(Y653, Y675, Y742, and Y823) and that are required for the recruitment of PI3K and
activation of the downstream PI3K/AKT pathway in response to IGF-1 and insulin
stimulation (33). PyMT:Irs1/2/ cells expressing equivalent levels of Irs2 or Irs2-Y5F, an
Irs2 mutant in which the essential tyrosines have been mutated to phenylalanine to
prevent PI3K recruitment (Fig. 1C and D), were examined for their invasive potential.
Cells expressing Irs2-Y5F showed a modest but signiﬁcant increase in invasion over EV
cells, but they were signiﬁcantly less invasive than cells expressing wild-type (WT) Irs2
(Fig. 1E). To conﬁrm the results of the two-dimensional (2D) Matrigel Transwell assay,
cells were grown within a Matrigel-collagen I matrix to assess invasive potential in a
three-dimensional (3D) environment that mimics the tumor matrix microenvironment
in vivo (34). Poorly/less invasive cells grow as spherical colonies in this 3D matrix,
whereas invasive cells invade the matrix to form branched colonies. Although Irs2- and
Irs2-Y5F-expressing cells formed similar numbers of colonies, cells expressing Irs2-Y5F
were signiﬁcantly less invasive than cells expressing Irs2 (Fig. 1F). Our data support the
notion that Irs2-dependent PI3K activation contributes to invasion. However, the partial
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FIG 1 IR/IGF-1R contributes to IRS2-mediated tumor cell invasion. PyMT:Irs1/2/ cells expressing EV or IRS2 were treated with
dimethyl sulfoxide (DMSO) or BMS754807 at the concentrations indicated for 4 h. (A) Matrigel Transwell invasion assays were
performed for 5 h. The data shown represent the means  standard errors of the mean (SEM) from three independent
experiments. ns, no signiﬁcant difference; **, P  0.01 relative to EV-DMSO; ##, P  0.01 relative to IRS2-DMSO. (B) Cells were
stimulated with IGF-1 (50 ng/ml) for 5 h in the presence or absence of BMS754807. Cell extracts containing equivalent amounts
of protein were immunoblotted with antibodies speciﬁc for IRS2, p-IGF-1R (Y1135/1136)/pIR (Y1150/1151), IGF-1R, pAKT (S473),
AKT, or tubulin. (C) Schematic of Irs2 and Irs2-Y5F proteins. (D) Cell extracts from PyMT:Irs1/2/ cells expressing EV, Irs2, or
Irs2-Y5F were immunoblotted with antibodies speciﬁc for IRS2 and tubulin. (E and F) PyMT:Irs1/2/ cells expressing EV, Irs2,
or Irs2-Y5F were assayed for invasion. (E) Matrigel Transwell invasion assay. The data shown represent the means and SEM of
the results of three independent experiments. (F) Matrigel-collagen I 3D invasion assay. The data shown represent the means
and SEM of the results of a representative experiment performed three times independently. Representative images of
colonies are shown on the right (magniﬁcation, 10). **, P  0.01 relative to EV; #, P  0.05 relative to IRS2; ##, P  0.01
relative to IRS2. Molecular weight markers (in kilodaltons) are indicated to the left of the immunoblots.
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reduction of invasion with the Irs2-Y5F mutant and the ability of IRS1 to activate PI3K
imply that additional mechanisms also contribute to this regulation.
The IRS2 C-terminal tail participates in the regulation of invasion. The IRS
proteins lack stable tertiary-domain structure, with the exception of N-terminal PH and
PTB domains that mediate recruitment to upstream receptors. To identify additional
sequence requirements of IRS2 for promoting invasion, we sought to identify regions
of the protein that are required for this functional outcome while preserving the ability
of IRS2 to be recruited to upstream receptors and to interact with and activate PI3K. To
do so, we generated an IRS2 truncation mutant lacking the C-terminal tail 3= to the PI3K
binding sites (IRS2Δ917) (Fig. 2A). A corresponding truncation mutant was also gener-
ated for IRS1 (IRS1Δ942) (Fig. 2A). Wild-type and mutant proteins were expressed in
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FIG 2 The IRS2 C-terminal tail regulates tumor cell invasion. (A) Schematic of WT and mutant IRS proteins. (B) PyMT:Irs1/2/ cells were
stimulated with IGF-1 (50 ng/ml) for 10 min, and cell extracts were immunoprecipitated (IP) with an HA-speciﬁc antibody and
immunoblotted with antibodies speciﬁc for HA or the p85 subunit of PI3K (p85). Whole-cell extracts (WCE) were also immunoblotted with
antibodies speciﬁc for HA, pAkt (S473), pAkt (T308), Akt, and tubulin. (C and D) PyMT:Irs1/2/ cells expressing IRS proteins were assayed
for invasion. (C) Matrigel Transwell invasion assays. The data shown represent the means and SEM of the results of three independent
experiments. (D) Matrigel-collagen I 3D invasion assays. The data shown represent the means and SEM of the results of a representative
experiment performed three times independently. Representative images of colonies are shown below (magniﬁcation, 10). (E)
SUM-159:IRS1/2/ cells expressing IRS proteins were assayed for invasion in a Matrigel Transwell invasion assay. The data shown
represent the means and SEM of the results of four independent experiments. *, P  0.05 relative to EV; **, P  0.01 relative to EV; ##,
P  0.01 relative to IRS2. Molecular weight markers (in kilodaltons) are indicated to the left of the immunoblot.
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PyMT:Irs1/2/ cells, and their abilities to interact with the PI3K regulatory subunit p85
in response to IGF-1 stimulation were examined. Both truncation mutants recruited
PI3K in response to IGF-1 stimulation (Fig. 2B). To examine further the role of the
C-terminal tail in the function of the IRS proteins, IRS1-IRS2 and IRS2-IRS1 chimeras were
generated by swapping the corresponding C-terminal regions of each adapter protein
(Fig. 2A). The chimeric proteins also maintained the ability to recruit PI3K. The IRS
proteins are required for IGF-1R-dependent stimulation of PI3K activation, as evidenced
by the lack of AKT activation in PyMT:Irs1/2/ cells in response to IGF-1 stimulation
(Fig. 2B, lane EV). Expression of either IRS1 or IRS2 restored the ability of IGF-1 to
promote AKT phosphorylation at both the Thr308 and Ser473 sites, and Akt activation
was maintained upon truncation or swapping of the C-terminal tails (Fig. 2B). Therefore,
the C-terminal regions of IRS1 and IRS2 are not required for the IGF-1-dependent
activation of the PI3K/AKT pathway.
Consistent with previous studies that have implicated IRS2 but not IRS1 in the
promotion of tumor cell invasion, PyMT:Irs1/2/ cells expressing IRS1 or the IRS1
truncation mutant (IRS1Δ942) invaded similarly to cells expressing EV (Fig. 2C). In
contrast, truncation of the IRS2 C-terminal tail (IRS2Δ917) inhibited invasion relative to
WT IRS2, indicating that sequences contained within the region are important for
IRS2-dependent regulation of this function. To examine the sufﬁciency of the IRS2
C-terminal tail to enhance invasion, cells expressing the IRS1-IRS2 chimera, which
contains the N-terminal portion of IRS1 and the C-terminal tail of IRS2, were assayed for
their invasive potential. PyMT:Irs1/2/ cells expressing the IRS1-IRS2 chimera exhib-
ited an increase in invasion equivalent to what was observed for cells expressing WT
IRS2. In contrast, cells expressing the IRS2-IRS1 chimera, which contains the N-terminal
portion of IRS2 and the C-terminal tail of IRS1, failed to increase invasion above that of
EV control cells (Fig. 2C). Cells expressing either WT IRS2 or the IRS1-IRS2 chimera also
grew in a highly invasive manner within the Matrigel-collagen I matrix, whereas cells
expressing IRS2Δ917 or the IRS2-IRS1 chimera exhibited little to no invasion, and the
colonies formed were similar to those of cells expressing empty vector or IRS1 (Fig. 2D).
Similar invasion results were obtained when the WT IRS proteins and their truncation
mutants were expressed in an IRS1-IRS2 double-null SUM-159 human breast carcinoma
cell line that was generated by clustered regularly interspaced short palindromic repeat
(CRISPR)/Cas9 knockout (SUM-159:IRS1/2/ cells) (Fig. 2E). Taken together, these data
reveal that the C-terminal tail of IRS2 is both necessary and sufﬁcient for IRS-dependent
enhancement of invasion.
Identiﬁcation of a region within the IRS2 C-terminal tail that regulates invasion
but not glucose uptake. The IRS2Δ917 truncation mutant lacks the ﬁnal 421 amino
acids (aa) of the IRS2 protein. To dissect further how this region contributes to the
regulation of invasion, smaller truncation mutants that lacked either 324 amino acids
(IRS2Δ1014) or 150 amino acids (IRS2Δ1188) were generated (Fig. 3A). These deletion
mutants were expressed in PyMT:Irs1/2/ cells and assayed for their responses to
IGF-1 stimulation. As was observed for the larger truncation mutant (IRS2Δ917), dele-
tion of smaller regions of the IRS2 C-terminal tail did not prevent PI3K recruitment or
downstream AKT signaling (Fig. 3B).
PyMT:Irs1/2/ cells expressing the IRS2Δ1014 and IRSΔ1188 truncation mutants
were assayed for their invasive potential. Deletion of the C-terminal 150 amino acids
(IRS2Δ1188) did not inhibit the ability of IRS2 to promote invasion compared with
full-length IRS2 (Fig. 3C). In contrast, the IRS2Δ1014 mutant was deﬁcient in promoting
tumor cell invasion (Fig. 3C). These data indicate that sequences between amino acids
917 and 1188 are required for the ability of IRS2 to enhance tumor cell invasion. Internal
deletion mutants missing amino acids 917 to 1014 (IRS2ΔCONT) or 1014 to 1188
(IRS2ΔINV) were generated (Fig. 3A), and these mutants maintained the ability to
associate with PI3K and to activate the AKT pathway in response to IGF-1 stimulation
(Fig. 3D). Deletion of the 174 amino acids between positions 1014 and 1188 rendered
IRS2 incapable of promoting tumor cell invasion as measured by both Matrigel Trans-
well (Fig. 3E) and 3D Matrigel-collagen I (Fig. 3F) assays. However, IRS2 lacking the 95
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FIG 3 Identiﬁcation of a region in the IRS2 C-terminal tail that regulates tumor cell invasion. (A) Schematic of WT and mutant IRS2
proteins. (B) Cell extracts from PyMT:Irs1/2/ cells stimulated with IGF-1 (50 ng/ml) for 10 min were immunoprecipitated with an
HA-speciﬁc antibody and immunoblotted with antibodies speciﬁc for HA or the p85 subunit of PI3K. Whole-cell extracts were also
immunoblotted with antibodies speciﬁc for HA, pAkt (S473), pAkt (T308), Akt, and tubulin. (C) Matrigel Transwell invasion assays. The
data shown represent the means and SEM of the results of ﬁve independent experiments. (D) Cell extracts from PyMT:Irs1/2/ cells
stimulated with IGF-1 (50 ng/ml) for 10 min were immunoprecipitated with an HA-speciﬁc antibody and immunoblotted with
antibodies speciﬁc for HA or the p85 subunit of PI3K. Whole-cell extracts were also immunoblotted with antibodies speciﬁc for HA,
pAkt (S473), Akt, and tubulin. The data shown in the graph below represent the means and SEM of p85 association with the IRS
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invasion assays. The data shown represent the means and SEM of the results of three experiments. (F) Matrigel-collagen I 3D invasion
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independently. *, P  0.05 relative to EV; **, P  0.01 relative to EV; #, P  0.05 relative to IRS2; ##, P  0.01 relative to IRS2. Molecular
weight markers (in kilodaltons) are indicated to the left of the immunoblots.
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amino acids between positions 917 and 1014 maintained full invasive potential (Fig. 3E
and F).
We previously identiﬁed a role for IRS2 in the regulation of glucose uptake that is
dependent upon the recruitment and activation of PI3K (13, 33). Knocking down the
essential glucose transporter GLUT1 inhibited mammary tumor cell invasion, support-
ing a requirement for glucose uptake in invasion. To determine if the IRS2 C-terminal
tail also participates in the regulation of glucose metabolism, PyMT:Irs1/2/ cells
expressing WT IRS1, WT IRS2, IRS2Δ917, and the two internal deletion mutants
(IRS2ΔCONT and IRS2ΔINV) were assayed for glucose uptake. Cells lacking IRS protein
expression (EV) or expressing only IRS1 did not increase glucose uptake signiﬁcantly in
response to IGF-1 stimulation (Fig. 4). In contrast, expression of WT IRS2 signiﬁcantly
enhanced the rate of IGF-1-stimulated glucose uptake (Fig. 4). Moreover, the full IRS2
C-terminal-tail deletion (IRS2Δ917) and the internal deletion mutants (IRS2ΔCONT and
IRS2ΔINV) also increased glucose uptake in response to IGF-1 (Fig. 4). Therefore, the
disruption of tumor cell invasion observed for the IRS2ΔINV mutant is not the result of
deﬁcient glucose uptake in these cells. Importantly, the ability of IRS2 to regulate
invasion can be separated from its regulation of glucose metabolism.
The INV region mediates essential interactions that promote invasion. Given
that IRS2 is an adaptor protein that lacks intrinsic kinase activity and mediates its
functions through the recruitment and activation of signaling effectors, we hypothe-
sized that intermolecular interactions that contribute to IRS2-dependent invasion occur
within the INV region. To investigate further if essential interactions occur within this
INV region, mVenus-tagged constructs containing the 174-aa INV region (aa 1014 to
1188), as well as two additional C-terminal regions (aa 917 to 1014 and 1188 to 1334)
(Fig. 5A) that are not required for regulating invasion (Fig. 3), were generated. These
mVenus-tagged regions were expressed by lentiviral infection and selection in SUM-
159 breast carcinoma cells (Fig. 5B). Expression of the C-terminal regions did not alter
the expression of endogenous IRS2 or interfere with IGF-1R-dependent PI3K/AKT
activation (Fig. 5C). However, the INV region decreased invasion signiﬁcantly (Fig. 5D).
A decrease in invasion was also observed when the INV region was expressed in
invasive human triple-negative MDA-MB-231 breast carcinoma cells (Fig. 5E).
The ability of the INV region to act in a dominant-negative manner and inhibit
invasion suggested that there are binding partners of this region of IRS2 that are
important for the regulation of invasion. To identify novel interacting proteins, we used
tandem afﬁnity puriﬁcation, followed by mass spectrometry (TAP-MS). For this purpose,
the IRS2-INV region (aa 1014 to 1188) was tagged with a ﬂexible 3Flag-6His tag and
transiently transfected into SUM-159 cells. TAP-MS analysis identiﬁed several interact-
ing proteins of the INV region, including desmoplackin, desmoglein, and desmocollin-1,
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FIG 4 The INV region is not required for the IRS2-dependent regulation of glucose uptake. PyMT:Irs1/
2/ cells were grown in 0.1% BSA-DMEM with or without IGF-1 (25 ng/ml) for 16 to 24 h. Glucose uptake
was measured and normalized to cell density. The data shown represent the means  SEM of the results
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which are members of the desmosome cell adhesion complex (35). In addition, the INV
region pulled down bone morphogenetic protein 2-inducible kinase (BMP2K), a serine
threonine kinase that has been previously reported to play a role in osteoblast
differentiation (36, 37). Given the potential of BMP2K to function as a signaling kinase
downstream of IRS2, we validated its interaction with full-length IRS2. BMP2K-speciﬁc
antibodies coimmunoprecipitated IRS2, and this interaction was enhanced in IGF-1-
stimulated cells (Fig. 6A). Although the BMP2K antibody recognizes all three human
BMP2K isoforms (BMP2K-1, -2, and -3) by immunoblotting, only BMP2K-2 and BMP2K-3
were present in the immunoprecipitation. BMP2K isoforms 2 and 3 lack the C-terminal
half of BMP2K-1, which supports the idea that IRS2 interacts with the N-terminal portion
of BMP2K.
To assess the contribution of BMP2K to IRS2-dependent invasion, short hairpin RNAs
(shRNAs) targeting BMP2K were expressed in PyMT:Irs1/2/ cells expressing WT-IRS2.
There are only two murine isoforms of Bmp2k, and the expression of both Bmp2k-1 and
Bmp2k-2 was decreased by 95% (Fig. 6B). Suppression of Bmp2k expression signiﬁ-
cantly decreased the IRS2-dependent enhancement of invasion (Fig. 6C). Akt activation
was not inhibited by the loss of Bmp2k expression, indicating that Bmp2k is not
required for IRS2-dependent PI3K activation (Fig. 6D).
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DISCUSSION
Our study identiﬁes a novel invasion-promoting region within IRS2 and advances
the mechanistic understanding of how IRS1 and IRS2 regulate distinct functional
outcomes. We established that the ability of IRS2 to promote invasion is dependent
upon upstream IGF-1R/IR activation and recruitment and activation of PI3K, functions
that are shared by IRS1. However, additional sequences within the C-terminal tail of
IRS2 are also required for IRS2-mediated invasion, and these sequences were sufﬁcient
to confer the ability to promote invasion when swapped into IRS1. A 174-amino-acid
region within the IRS2 C-terminal tail, which we term the INV region, is essential for
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FIG 6 BMP2K interacts with IRS2 and contributes to IRS2-dependent invasion. (A) MDA-MB-231 cells expressing IRS2-
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enhancing invasion. Importantly, the INV region is not required for the IRS2-dependent
regulation of glucose uptake, which provides evidence that IRS2 functions important
for cancer progression can be disrupted while preserving the metabolic functions of the
adaptor protein. We demonstrated that the INV region acts in a dominant-negative
manner to inhibit invasion when expressed exogenously and identiﬁed BMP2K as one
binding partner that interacts with this region and contributes to IRS2-dependent
invasion. Taken together, our data highlight the important role of the IRS C-terminal
tails in determining the unique functions of these adaptor proteins and identify a novel
mechanism by which IRS2 regulates invasion.
Our structure/function analysis of IRS2 revealed important mechanistic information
regarding how the IRS proteins regulate their unique functions. The IRS proteins are
most similar in their N-terminal PH and PTB domains, and they are recruited to common
cell surface receptors through these structured regions (38). C-terminal to these do-
mains, the IRS proteins are less homologous across family members, although tyrosine
residues located within canonical SH2 domain binding motifs are conserved. PI3K,
GRB2, SHP2, and SFKs are recruited to these phosphotyrosine sites in both IRS1 and
IRS2, and therefore, these interactions are not sufﬁcient to explain their divergent
functions (19–23). However, our data establish that the C-terminal tails do play an
important role in their unique functional properties, as swapping these regions be-
tween IRS1 and IRS2 confers on IRS1 the ability to regulate invasion. The intrinsically
disordered nature of the IRS C-terminal tails is proposed to facilitate dynamic structural
changes in response to upstream stimuli to allow rapid recruitment and activation of
signaling effectors. This model is based upon another adaptor protein, Gab1, which has
a structured PH domain in the N terminus and a long, disordered C-terminal tail, similar
to the IRS proteins (30). Phosphorylation of a serine residue in the Gab1 tail alters
intramolecular interactions with the PH domain to generate “loop structures” that serve
as docking sites for signaling effectors (39). We predict that sequences within the INV
region in the IRS2 C-terminal tail participate in intramolecular interactions to form
binding domains for unique effectors, such as BMP2K, that cooperate with PI3K to
regulate invasion (Fig. 7).
We identiﬁed BMP2K as a novel IRS2-interacting protein that contributes to the
ability of IRS2 to promote invasion. BMP2K, also known as BIKE (36), is a member of the
human Numb-associated protein kinase (NAK) family, which also includes adaptor-
associated kinase 1 (AAK1), cyclin G-associated kinase (GAK), and myristoylated and
palmitoylated serine/threonine kinase 1 (MPSK1) (37). The limited information about
BMP2K includes a role in attenuating osteoblast differentiation and genetic association
FIG 7 Model of IRS2 function. Upstream receptor activation stimulates dynamic intramolecular interac-
tions within IRS2 that facilitate recruitment of PI3K and BMP2K to enhance invasion. SS, disulﬁde bond;
P, tyrosine phosphorylation site.
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with myopia and hip dysplasia (36, 40, 41). BMP2K has also been identiﬁed as a
clathrin-coated-vesicle-associated protein, likely through its interaction with NUMB, a
tumor suppressor that regulates endocytic receptor trafﬁcking (42, 43). Trafﬁcking of
growth factor and integrin receptors has been implicated in cancer cell migration and
invasion (44, 45), and this could be one mechanism by which BMP2K contributes to
IRS2-dependent invasion. BMP2K is a constitutive kinase based upon its crystal struc-
ture, but its substrates are unknown (46). Future identiﬁcation of these substrates will
be important for elucidation of the mechanism by which BMP2K contributes to
IRS2-dependent invasion.
The ability of IRS2 to enhance invasion is dependent upon the activation of PI3K.
IRS1 also activates PI3K, but the functional outcome of this signaling is proliferation, not
invasion (47). How each of these adaptor proteins can activate PI3K in response to
common upstream receptor stimuli but regulate diverse functional outcomes has
remained an open question. Although the INV region is not required for the recruit-
ment and activation of PI3K, binding partners that interact with the region may
cooperate with PI3K to enhance invasion. Alternatively, interactions with the region
could modify the downstream outcomes of PI3K signaling to elicit divergent outcomes.
In this regard, the differential requirement for an intact microtubule cytoskeleton in the
IRS-dependent activation of AKT suggests that one mechanism by which interactions
with the INV region could alter PI3K signaling outcomes is through the regulation of
IRS2 trafﬁcking that localizes PI3K signaling to intracellular locations necessary for
regulating invasion (48). This could impact access to distinct pools of PI3K downstream
effectors that promote invasion. Although BMP2K is not required for PI3K activation, the
interaction of BMP2K with NUMB could impact endocytic trafﬁcking and contribute to
this mechanism of differential signaling. Interactions that regulate the strength and
duration of the PI3K signal could also determine differential downstream functional
outcomes. For example, interaction of the HECT-type ubiquitin ligase NEDD4 with IRS2
promotes monoubiquitination of C-terminal lysine residues (49). This ubiquitin modi-
ﬁcation promotes IGF-1-dependent tyrosine phosphorylation of IRS2 and enhances
downstream signaling. However, NEDD4 binds to IRS2 through its conserved PH and
PTB domains, not the INV region, and the speciﬁcity of this mechanism of regulation for
IRS2, and not IRS1, has not been demonstrated (49).
A key outcome of our study is the demonstration that the mechanism by which IRS2
regulates invasion is distinct from the mechanism by which it regulates glucose uptake.
Although the two IRS2 functions share a requirement for PI3K activation, as demon-
strated by the deﬁciency of cells expressing the Irs2-Y5F mutant that is defective in PI3K
recruitment in invading or enhancing glucose uptake (33), the INV region is uniquely
required for regulating invasion. These mechanistic differences could be exploited to
selectively target IRS2-mediated invasion, which contributes to metastasis, without
affecting IRS2-mediated metabolic processes in normal tissues. Drugs that target IGF-1R
have been investigated in clinical trials for several types of cancer, and the results
overall have been disappointing, as multiple speciﬁc inhibitors have failed to show
efﬁcacy in preventing disease progression (50, 51). One reason for the failure of IGF-1R
inhibitors is the upregulation of the insulin receptor to compensate for the loss of
IGF-1R signaling (52, 53), but targeting both receptors disrupts normal metabolic
homeostasis. Our results provide a rationale for considering IRS2 and IRS2-interacting
proteins viable alternative targets for the inhibition of the IGF-1R/IR pathway in cancer.
The identiﬁcation of the INV region and BMP2K opens the door to developing novel
approaches that would allow the disruption of tumor functions while maintaining
normal metabolic function.
MATERIALS AND METHODS
Cells and transfection. MDA-MB-231 cells were obtained from the ATCC Cell Biology Collection and
grown in RPMI medium (Gibco) containing 10% fetal bovine serum (FBS) (Sigma). SUM-159 cells were a
kind gift from Stephen Ethier (University of Michigan) and were grown in F-12 medium (Gibco)
containing 5% FBS (Sigma), 5 g/ml insulin (Sigma), and 1 g/ml hydrocortisone (Sigma). PyMT cells
were grown in low-glucose (1-g/liter) Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Corning) containing
IRS2 Regulation of Invasion Molecular and Cellular Biology
July 2018 Volume 38 Issue 14 e00590-17 mcb.asm.org 11
 o
n
 July 12, 2018 by UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
10% FBS. All the cells tested negative for mycoplasma using the Morwell MD Biosciences EZ PCR
mycoplasma test kit (no. 409010).
PyMT mammary tumor cells were isolated from female FVB MMTV-PyMT:Irs1ﬂ/ﬂIrs2ﬂ/ﬂ mice, and
PyMT:Irs1/ Irs2/ cells were generated by infection with adenoviral Cre recombinase as described
previously (33). IRS1/IRS2 double-null SUM-159 cells were generated by CRISPR/Cas9-mediated gene
editing using guide RNAs (gRNAs) that targeted an early 5= exon region for either IRS1 (gRNA sequence:
GCATGCTCTTGGGTTTGCGCAGG) or IRS2 (gRNA sequence: AACCACAGCGTGCGCAAGTGCGG). The gRNAs
were subcloned into the pSpCas9(BB)-2A-GFP plasmid (Addgene; 48138). Cells were transfected with the
CRISPR plasmid containing the IRS1 gRNA using Lipofectamine 2000 (Invitrogen) and sorted by ﬂow
cytometry for the green ﬂuorescent protein (GFP)-high population to obtain IRS1/ cells. The IRS1/
cells were transfected with the CRISPR plasmid containing the IRS2-speciﬁc gRNA and sorted for
GFP-high cells to generate SUM-159:IRS1/ IRS2/ cells. The cells were transfected with human IRS1,
IRS2, and IRS mutants in pcDNA3.1 and selected in 500 g/ml G418 (Gibco).
Mutagenesis and cloning. Hemagglutinin (HA)-tagged human IRS1 and IRS2 were kindly provided
by Adrian Lee (University of Pittsburgh, Pittsburgh, PA). Murine Irs2 was a kind gift from Morris White
(Children’s Hospital, Boston, MA), and the Irs2-Y5F mutant was generated as described previously (33).
Human IRS deletions and chimeras were generated by PCR ampliﬁcation using Q5 Hot Start High-Fidelity
DNA polymerase (M0493S; New England BioLabs), and the PCR products were ligated into vectors using
a Quick Ligation kit (M2200S; New England BioLabs). IRS chimeras were generated by PCR ampliﬁcation
of IRS1 and IRS2 N-terminal and vector sequences and C-terminal sequences. An AgeI site was introduced
into both sections without altering the amino acid sequence (underlined in primer sequences in Table
1). IRS1-IRS2 and IRS2-IRS1 chimeras were generated by digestion of the PCR products with AgeI and
HindIII and ligation of the swapped C-terminal regions with the IRS1 and IRS2 N termini. mVenus-tagged
IRS2 regions were generated by PCR ampliﬁcation from pcDNA-IRS2-HA and digestion with NheI and NotI
overnight. The digested PCR products were ligated into the pCDH-mVenus vector that was generated by
ligation of mVenus from the mVenus N1 plasmid (Addgene; 27793). The PCR primers (Table 1) were
purchased from Integrated DNA Technologies.
Invasion assays. Matrigel Transwell invasion assays were performed as described previously (1, 54).
Cells were preincubated with BMS754807 (S1124; Selleckchem) for 4 h prior to the assays, and the
inhibitor was also present in the upper and lower wells of the Transwell chamber during the assays. For
3D invasion assays, cells were suspended in a mixture of Matrigel (2 mg/ml) and collagen I (1 mg/ml) and
plated over a base gel layer of the same matrix composition in 8-well chamber glass slides (Falcon). The
gel was overlaid with complete-serum-containing medium, which was changed every 2 days for 8 days.
All colonies were imaged and scored for the extent of cell invasion/branching (Diaphot 300 microscope;
Nikon, Melville, NY) after 8 days. Matrigel (number 354230) and collagen I (number 354236) were
obtained from Corning Discovery Labware, Inc. (Bedford, MA).
Immunoblotting and immunoprecipitation. Cells were serum starved overnight (human cells) or
for 4 h (PyMT cells) in serum-free medium. The cells were stimulated with human recombinant IGF-1
(R&D Systems, Minneapolis, MN) for the time periods indicated in the ﬁgure legends prior to extraction.
For whole-cell extract immunoblots, cells were solubilized at 4°C in RIPA lysis buffer (25 mM Tris, pH 8.0,
TABLE 1 Primers used for PCR
Primer name Primer sequencea
IRS1Δ942-fwd 5= TACCCCTACGACGTCCC 3=
IRS1Δ942-rev 5= CTGAGCAGCTGTGTCCAC 3=
IRS2Δ917-fwd 5= TACCCCTACGACGTCCC 3=
IRS2Δ917-rev 5= AGGCACTACAGGGTGAGG
IRS2Δ1014-fwd 5= TACCCCTACGACGTCCC 3=
IRS2Δ1014-rev 5= ATACGGGGAGGAGGCCT 3=
IRS2Δ1188-fwd 5= TACCCCTACGACGTCCC 3=
IRS2Δ1188-rev 5= GCCCTCGCTGCTTTTCCT 3=
IRS2ΔCONT-fwd 5= CCGCCGTTGCCCCCG 3=
IRS2ΔCONT-rev 5= GGGCTCGCCAAAGTCGATG 3=
IRS2ΔINV-fwd 5= GGCGTGGGTGTCGGC 3=
IRS2ΔINV-rev 5= ATACGGGGAGGAGGCCT 3=
IRS1/S2:C-term tail-fwd 5= TCAGACCGGTTGGGCGCATCCTGGAGGAG 3=
IRS1/S2:C-term tail-rev 5= GAAGGCACAGTCGAGGCTGA 3=
IRS1/S2:N-term IRS1/Vector-fwd 5= AGCGCCTATGCCAGCATC 3=
IRS1/S2:N-term IRS1/Vector-rev 5= CTGAACCGGTGTGTCCACCTTTCGAGGC 3=
IRS2/S1:C-term tail-fwd 5= TCAGACCGGTGCCTCGAAAGGTGGACACA 3=
IRS2/S1:C-term tail-rev 5= GAAGGCACAGTCGAGGCTGA 3=
IRS2/S1:N-term IRS1/Vector-fwd 5= GGAGGCCACCATCGTGAAAG 3=
IRS2/S1:N-term IRS1/Vector-rev 5= ATGCACCGGTGACGACATGAGCACGTACTGGTCGC 3=0
IRS2:917-1014-fwd 5= CTCAAGCTTGGGGCCCGCCTGTCG 3=
IRS2:917-1014-rev 5= ACCGTCGACCCACCGCCTCCGGAATACGGGGAGGAGGCCTC 3=
IRS2:1014-1188-fwd 5= CTCAAGCTTCCGCCGTTGCCCCCG 3=
IRS2:1014-1188-rev 5= ACCGTCGACCCACCGCCTCCGGAGCCCTCGCTGCTTTTCCT 3=
IRS2:1188-1334-fwd 5= CTCAAGCTTGGCGTGGGTGTCGGC 3=
IRS2:1188-1334-rev 5= ACCGTCGACCCACCGCCTCCGGACTCTTTCACGATGGTGGCCT 3=
IRS2:1014-1188-3XFLAG6XHis-fwd 5= CTCTCTAGAATGCCGCCGTTGCCCCCG 3=
IRS2:1014-1188-3XFLAG6XHis-rev 5= CTAGGAATTCGCCCTCGCTGCTTTTCCT 3=
aAgeI sites are underlined.
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0.1% sodium dodecyl sulfate, 1% sodium deoxycholate, 1% Nonidet P-40, 150 mM sodium chloride, 10
mM sodium ﬂuoride, 1 mM sodium orthovanadate) containing protease inhibitors (Roche, Basel, Swit-
zerland). Cell extracts containing equivalent amounts of protein were resolved by SDS-PAGE and
transferred to nitrocellulose membranes. The membranes were blocked for 1 h with a 50 mM Tris buffer,
pH 7.5, containing 0.15 M NaCl, 0.05% Tween 20, and 5% (wt/vol) dry milk or 5% bovine serum albumin
(BSA); incubated overnight at 4°C in the same buffer containing primary antibodies; and then incubated
for 1 h in 5% blocking buffer with milk containing peroxidase-conjugated secondary antibodies. Proteins
were detected by enhanced chemiluminescence (Bio-Rad, Hercules, CA).
For immunoprecipitations, cells were extracted in either a 20 mM Tris buffer, pH 7.4, containing 1%
Nonidet P-40, 0.137 M NaCl, 10% glycerol, 10 mM sodium ﬂuoride, 1 mM sodium orthovanadate, and
protease inhibitors (Roche) or a 40 mM HEPES buffer, pH 7.5, containing 120 mM NaCl, 1% Triton X-100,
10 mM sodium ﬂuoride, 1 mM sodium orthovanadate, and protease inhibitors (Roche). Aliquots of cell
extracts containing equivalent amounts of protein were precleared for 30 min with IgG and protein
G-Sepharose beads and then incubated for 3 h or overnight at 4°C with speciﬁc antibodies and protein
G-Sepharose beads (GE Healthcare) with constant agitation. The beads were washed three times in
extraction buffer. Laemmli sample buffer was added to the samples, and immune complexes were
resolved by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted as described above.
The following antibodies were used for immunoblotting and immunoprecipitation: IRS2 (4502; Cell
Signaling, Danvers, MA), p85 (05-212; Millipore, Billerica, MA), HA (11867423001; Roche), phospho-IGF-
1R (Y1135/1136)/IR (Y1150/1151) (3024; Cell Signaling), IGF-1R (3025; Cell Signaling), phospho-AKT
S473 (9271 and 4060; Cell Signaling), phospho-AKT T308 (2965; Cell Signaling), AKT (sc-8312, Santa Cruz;
9272, Cell Signaling), BMP2K (sc-134284; Santa Cruz), -tubulin (T5168; Sigma-Aldrich), GFP (ab6556;
Abcam), HA (11867423001; Roche), peroxidase-conjugated goat anti-rabbit IgG (111-035-144; Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA), and peroxidase-conjugated goat anti-mouse IgG
(711-035-151; Jackson ImmunoResearch Laboratories, Inc.).
Tandem afﬁnity puriﬁcation and mass spectrometry. SUM-159 cells transiently expressing INV-
3Flag-6His were extracted in a 50 mM Tris, pH 7.4, buffer containing 250 mM NaCl, 0.1% Triton X-100,
10 mM sodium ﬂuoride, 1 mM sodium orthovanadate, and protease inhibitors (Roche). Aliquots of cell
extracts were incubated for 3 h with FLAG-M2 agarose beads (Sigma) that had been equilibrated in lysis
buffer. The beads were washed and eluted with 3 FLAG peptide (Sigma) diluted in lysis buffer. The
FLAG elution was incubated with Talon (Millipore) agarose beads for 2 h before washing and elution with
lysis buffer containing 250 mM imidazole. The Talon bead elution was trichloroacetic acid (TCA)
precipitated and reconstituted in 1 Laemmli sample buffer. Samples were resolved by SDS-PAGE and
analyzed by liquid chromatography-tandem mass spectrometry (LC–MS-MS) at the University of Massa-
chusetts Medical School Mass Spectrometry Facility.
Glucose uptake assays. Cells were grown to near conﬂuence, washed with phosphate-buffered
saline (PBS), and then incubated in 0.1% BSA-DMEM (1 g/liter glucose) for 16 to 24 h in the presence or
absence of IGF-1 (25 ng/ml). Glucose levels were measured using a glucose assay kit (Sigma) according
to the instructions of the manufacturer. Cell density per well was determined by crystal violet staining,
and glucose uptake was expressed as a rate measurement (millimolar per milligram per hour) normalized
to the cell density.
Statistical analysis. Statistical analysis between two groups was performed using the two-tailed
unpaired Student t test. A P value of 0.05 was considered to indicate statistical signiﬁcance.
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